Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas is supported by a de-risked balance sheet and a clearer strategic focus after the VEPPANU partnership with Rigel delivered $85M upfront plus up to $320M in milestones and royalties, while also removing a major commercial overhang. The company’s stock still trades near cash, with management guiding a cash runway into 2H28, which gives investors downside protection while several wholly owned programs advance toward 2026 data readouts. Fundamentally, the bull case rests on a differentiated PROTAC platform and multiple catalysts across oncology and neurology, including compelling ARV-102 biomarker activity and promising ARV-806, ARV-393, and ARV-6723 development paths.

Arvinas is facing a fundamentally pressured outlook because its pipeline remains highly dependent on clinical execution while key assets have shown only immature or uncertain signs of activity, including ARV-806 being reprioritized toward out-licensing after early monodose escalation data. The company also carries meaningful development and financing risk, since advancing multiple protein-degradation programs through trials and potential commercialization will require substantial capital, while reliance on CMOs and the possibility of regulatory setbacks could delay or suspend progress. Although ARV-102 has a clearer PSP path with a ~30K-patient, unmet-need indication and planned 50+ patient phase 1b and registrational phase 2 studies, the FDA clinical hold and need for final chronic tox data underscore how fragile the timeline remains.